
RSV Raises Risk for Diverse Complications Across Adulthood
In a study of nearly 45,000 individuals published online in Influenza and Other Respiratory Viruses , Wang Chun Kwok, MD, of the University of Hong Kong, Hong Kong, and colleagues compared data from 41,206 adult patients hospitalized with flu and 3565 hospitalized for RSV infections at centers in Hong Kong.
Overall, patients with RSV infection had significantly higher risk not only for in-patient mortality but also severe respiratory failure, secondary bacterial pneumonia, and acute kidney injury than patients with flu ( P < .001 for all).
In addition, the researchers highlighted end-stage kidney disease requiring renal replacement therapy as a significant independent risk factor for poor outcomes among the RSV patients, with an adjusted odds ratio of 4.74 for in-hospital mortality ( P < .001).
The patients with RSV infection also were stratified by age based on current US recommendations for RSV vaccination (aged 60 years and older, younger than 60 years, and 50-59 years).
Notably, the findings of increased risk were consistent across all adult age groups, the researchers wrote. 'The risk factors for severe RSV infections demonstrated in this study provided insights on the target patient subgroups for vaccination, especially among countries and places with limited resources that do not allow vaccination for the entire population,' they concluded.
Flu vs RSV
The study by Kwok and colleagues provides an essential comparison, said Seyedmohammad Pourshahid, MD, assistant professor of thoracic medicine and surgery at the Lewis Katz School of Medicine at Temple University, Philadelphia, in an interview.
'For decades, influenza has set the standard in how we talk about vaccine-preventable adult respiratory disease, but with RSV vaccines now entering clinical use, it's critical to understand whether RSV deserves similar attention,' he said.
'The findings speak to more than just respiratory illness. The added burden of renal complications and secondary infections makes it clear that RSV can be a systemic threat, especially in hospitalized adults,' said Pourshahid. What stands out is that this pattern was seen across a range of adult ages, not just in the elderly, which challenges the current boundaries we draw around vaccine eligibility,' he added.
Limitations of the study include not only the retrospective design but also the impact of variables including coding accuracy, variability in care, and the effect of existing vaccine use for influenza, which all play a role in shaping outcomes, said Pourshahid. However, the consistent trends seen in the study point toward a need to reevaluate RSV prevention, he said.
'From a clinical perspective, this means not underestimating RSV, especially in patients with kidney or cardiopulmonary disease. From a public health perspective, it raises the question of whether our current vaccine recommendations are too narrow,' Pourshahid told Medscape Medical News . 'With further data, particularly post-vaccine implementation, we may find that the case for broader immunization is stronger than expected,' he said.
Additional studies should follow vaccinated patients to identify any changes in the patterns of complications, Pourshahid said. 'These kinds of real-world data will be essential in helping us understand not just whether the vaccine prevents RSV infection, but whether it also reduces the broader complications that come with it,' he said.
In another study, published in Clinical Infections Diseases, Paulina Sudnik, MD, of the University of Rochester, Rochester, New York, and colleagues found that approximately one-third of 471 adults hospitalized with RSV experienced a cardiovascular event (CVE) during the high-risk period of the first 28 days after hospital admission.
Previous studies support an association between respiratory viral infections such as influenza and COVID-19 and acute CVEs, but data on the patients with CVEs in the context of RSV are lacking, the researchers wrote.
The study population included 471 adults aged 18 years and older who were hospitalized for at least 24 hours with RSV. Overall, 174 of the patients (37%) experienced a total of 270 CVEs during the high-risk period. The most common CVE was congestive heart failure (25%), followed by atrial fibrillation or flutter (13%), and myocardial infarction (9%).
Although 44% of the CVEs occurred in patients with no prior history of CVEs, preexisting conditions including hypertension, congestive heart failure, atrial fibrillation, and coronary artery disease, or evidence of at least three classic cardiac risk factors were significantly associated with increased CVE risk among patients older than 65 years.
Additionally, the monthly incidence of CVE after RSV infection was significantly increased compared to the pre-infection period, with incidence rate ratios of 18.5 and 1.6 during the high-risk and low-risk periods, respectively, compared to the pre-RSV period.
The study was limited by several factors, including the retrospective design and a lack of data on subclinical cardiac injury and CVEs that were mild or occurred outside the hospital setting.
However, the results were strengthened by the comparison of CVE data before and after RSV hospitalization, and the data may inform clinical decision-making on RSV vaccination, the researchers concluded.
Translating Data Into Practice
The study by Sudnick and colleagues brings needed attention to a dimension of RSV that is often overlooked, Pourshahid said in an interview.
'While most clinical focus has been on its respiratory manifestations, this work shifts the lens to cardiovascular complications and raises important questions about who is truly at risk and how those risks unfold,' he said. 'The fact that many of the events occurred in people without known heart disease adds weight to the idea that RSV can act as a stressor, revealing latent disease or perhaps even provoking new events through inflammation and hemodynamic strain,' he added.
Several limitations prevent drawing broad conclusions from the study, Pourshahid told Medscape Medical News . 'The data come from a specific region and rely on retrospective review, which limits how far we can generalize, and hospitalized patients also tend to be monitored more closely, so we may be picking up events that would otherwise go unnoticed,' he said. However, these limitations don't detract from the message that the RSV's impact is wider than clinicians might often consider, he added.
Clinically, the data reinforce the importance of paying close attention to the cardiovascular profile of patients admitted with RSV, even those without known cardiac disease, and contribute to conversations among policy makers and vaccine and vaccine developers, he noted. 'Preventing RSV might mean preventing not just respiratory failure but also heart failure, arrhythmias, or ischemic events, which is an important shift in how we think about vaccine value,' he said.
Prospective studies that can look more closely at how these events happen, how often they recur, and whether vaccines can interrupt that trajectory,' Pourshahid said.
'As this study took place before RSV vaccines became available, we are in a key moment to begin tracking how the clinical picture changes in vaccinated populations,' he said.
Kwok and Desmond Yat Hin Yap disclosed receiving research support from GlaxoSmithKline.
The study by Sudnik and colleagues received no outside funding. Sudnik disclosed having no financial conflicts.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Fox News
an hour ago
- Fox News
Three-person IVF technique shown to prevent inherited genetic diseases
An unconventional approach to reproduction is reportedly reducing the risk of metabolic disease. Three-person in vitro fertilization (IVF), a new concept developed by scientists in New Castle, U.K., has resulted in the births of eight healthy children. In the study, published in The New England Journal of Medicine, the researchers found that pathogenic variants in mitochondrial DNA (mtDNA) are a "common cause" of severe — and often fatal — inherited metabolic disease. This DNA in the mother's mitochondria can cause "harmful mutations" in children, which can lead to diseases that affect tissues in the heart, brain and muscles, according to the journal Nature. At the Newcastle Fertility Centre, 22 women with pathogenic mtDNA variants underwent a "pronuclear transfer," in which they received a mitochondrial donation. This involved the transfer of the nucleus of a fertilized egg with "faulty mitochondria" into a donor egg cell with healthy mitochondria, Nature detailed. The result includes nuclear DNA from both the biological mother and father, as well as mitochondrial DNA from the separate egg donor. From this, eight children were born healthy, with no levels or low levels of mtDNA detected in their blood. The researchers noted that one child did develop hyperlipidemia (high cholesterol) and cardiac arrhythmia (irregular heartbeat) — as the child's mother had hyperlipidemia during pregnancy — but both conditions responded to treatment. Another child developed infant myoclonic epilepsy — a rare type of epilepsy that typically affects infants between 6 months and 3 years old — which concluded in "spontaneous remission." "At the time of this report, all the children have made normal developmental progress," the researchers noted. Dr. Zev Williams, director of Columbia University Fertility Center in New York City, said this latest research "marks an important milestone." "Expanding the range of reproductive options … will empower more couples to pursue safe and healthy pregnancies," he said in an interview with Fox News Digital. In a press briefing, Robert McFarland, a pediatric neurologist at Newcastle University, who co-led one of the studies, reportedly noted the team's "cautious optimism" about the results. "To see babies born at the end of this is amazing, and to know there's not going to be mitochondrial disease at the end of that," he said. Fox News Digital reached out to the study researchers for comment.
Yahoo
an hour ago
- Yahoo
Floss-based vaccine delivers flu antibodies to bone marrow, saliva, and more
Flossing might soon do more than protect your teeth. Scientists have developed a new vaccine delivery method that uses specialized dental floss to trigger an immune response, without the need for needles. In the study, researchers tested the novel technique by applying vaccine components such as proteins and inactivated viruses along the gum lines of mice. The floss-based approach effectively stimulated immunity and protected the rodents from a lethal flu strain. Flossing mice for science The team flossed 50 mice every two weeks over a 28-day period. One researcher gently pulled down each mouse's jaw using a keychain ring, while another flossed the gums with vaccine-laced strands. After four weeks and three flossing sessions, the mice faced a lethal dose of influenza. All of the vaccinated mice survived. Those that hadn't received the floss-based vaccine died. Researchers found signs of a systemic immune response in the flossed mice. Flu-fighting antibodies appeared in their feces, saliva, and bone marrow. That last discovery was key, antibodies in bone marrow suggest long-term immunity. The vaccinated group also showed elevated T cell levels in their lungs and spleens. T cells help the body destroy virus-infected cells and prevent future infections. The results suggest this flossing method doesn't just offer local protection in the mouth, but activates a strong immune response throughout the body, something that traditional mucosal vaccines have struggled to achieve. Testing for human feasibility To explore whether the technique might work in people, scientists recruited 27 healthy adults. Each participant used dental picks coated in food dye. On average, the dye reached gum tissue in about 60% of flossing attempts. That level of contact shows potential, though further refinement is needed for consistent delivery. The gums between teeth are highly permeable, which allows vaccine molecules to pass through more easily than skin or other tissues. The oral cavity is also a frontline entry point for viruses. But developing vaccines for the mouth and nose has proven difficult due to the body's natural resistance to foreign agents in these regions. Floss, however, might offer a way to bypass those defenses. 'These findings establish floss-based vaccination as a simple, needle-free strategy that enhances vaccine delivery and immune activation compared with existing mucosal immunization methods,' wrote the researchers. Pandemic-ready and needle-free Beyond effectiveness, this method offers practical advantages. Needle-phobic patients may be more willing to receive vaccines delivered via floss. The treatment also doesn't require cold-chain storage, which simplifies distribution. Floss-based vaccines could even be mailed to households during outbreaks, enabling faster, more widespread immunization during pandemics. While the method is still in early stages, it marks a significant step toward making vaccinations more accessible and less invasive. With further development, a daily health habit like flossing could double as disease prevention on a global scale. The study is published in Nature Biomedical Engineering. Solve the daily Crossword
Yahoo
2 hours ago
- Yahoo
UK-India $4.8bn FTA poised to benefit medtech and pharma
The UK and India's newly signed £4.8bn ($6.45bn) free trade agreement (FTA) is expected to give rise to new opportunities for Indian medical device and pharmaceutical manufacturers. Signed on 24 July, India's medical device and pharmaceutical industries expect the agreement to reduce the regulatory burden around Indian exports to the UK, which include contact lenses, diagnostic reagents, and surgical instruments. While the UK already has zero-duty access for Indian medical devices, the agreement means India will gradually phase down import duties on UK medical devices from 7.5%–15% to 3%, rendering British medical device exports more affordable to the Indian market. According to the Medical Technology Association of India (MTAI), the agreement will improve access to advanced medical technologies and enable joint ventures, skilling, and long-term ecosystem resilience. India is a strategic site for orthopaedics maker Smith+Nephew's manufacturing activities. Smith+Nephew CEO Deepak Nath commented: 'The FTA offers the potential to build trading links in the healthcare sector. 'We hope that the FTA will enable Smith+Nephew's innovative medical technologies to support more healthcare professionals.' While the FTA has been met with optimism by the medical device industry at large, some observers are concerned that Chinese-origin products could be routed through the UK to exploit the zero-tariff provisions under an India-UK FTA. A source from the India commerce ministry's Export Promotion Council of Medical Devices (EPCMD) told Mint: 'To prevent this, it is critical to enforce strict rules of origin, including a minimum of 55% UK content, excluding labour, packing, and shipping costs." Pharma impact Under the FTA, the Indian Pharmaceutical Alliance (IPA) secretary general Sudarshan Jain said: 'The pharma sector will have opportunities to supply affordable and quality assured medicine contributing to better patient care in the UK.' The FTA includes a clause for zero import duty to the UK on finished formulations, APIs, and bulk drugs that is expected to benefit generic drug makers in India. According to Namit Joshi, the chairman of government body Pharmaceuticals Export Promotion Council of India (Phaemexcil), the FTA agreement sets the stage for further collaborations between the countries in bulk drug imports, CDMO, and joint research initiatives. In 2024, UK imports of medicinal and pharmaceutical products from India totalled around £667.4m ($897.1m). An Indian commerce ministry official told Indian news agency PTI: 'Given the UK's shift away from reliance on Chinese imports post-Brexit and Covid-19, Indian manufacturers are poised to emerge as a favoured, cost-effective alternative.' "UK-India $4.8bn FTA poised to benefit medtech and pharma" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data